Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2014-000410-57 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To determine the safety, tolerability, pharmacokinetics, maximum tolerated dose, and recommended Phase II dose of BAY1143572 in a once-daily or an intermittent dosing schedule in subjects with advanced acute leukemia
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 20 mg BAY1143572 | Experimental | Subjects received 20 milligram (mg) BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle. |
|
| 40 mg BAY1143572 | Experimental | Subjects received 40 mg BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle. |
|
| 80 mg BAY1143572 | Experimental | Subjects received BAY1143572 80 mg tablet orally once daily from Cycle 1 Day 1 of each cycle. |
|
| 120 mg BAY1143572 | Experimental | Subjects received BAY1143572 120 mg tablet orally once daily from Cycle 1 Day 1 of each cycle. |
|
| 160 mg BAY1143572 | Experimental | Subjects received BAY1143572 160 mg tablet orally once daily from Cycle 1 Day 1 of each cycle. |
|
| 200 mg BAY1143572 |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atuveciclib, BAY1143572 | Drug | The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Tolerated Dose (MTD) of BAY1143572 in Advanced Acute Leukemia Subjects | The MTD was defined as the highest dose that could be given such that not more than 20% of subjects experience a dose limiting toxicity (DLT) during Cycle 1. The study was terminated prior to the determination of MTD and hence no data was presented. | After the first 28 days of treatment (cycle 1) |
| Maximum Total Observed Drug Concentration (Cmax) of BAY1143572 after Single Dose Administration in Plasma | Maximum total observed drug concentration of BAY1143572 after single dose administration in plasma was measured. | Pre-dose up to 24 hours post-dose on Cycle1 Day 1 |
| Maximum Total Observed Drug Concentration of BAY1143572 after Multiple Dose Administration in Plasma (Cmax,md) | Maximum total observed drug concentration of BAY1143572 after multiple dose administration in plasma was measured. | Pre-dose up to 24 hours post-dose on Cycle 1 Day 15 |
| Area Under the Concentration Versus Time Curve from Zero to 24 hours (AUC[0-24h]) of BAY1143572 in Plasma After Single Dose Administration | Area under the concentration versus time curve from zero to 24 hours of BAY1143572 in plasma after single dose administration was measured. | Pre-dose up to 24 hours post-dose on Cycle1 Day 1 |
| Area Under the Concentration Versus Time Curve from Zero to 24 hours of BAY1143572 in Plasma after Multiple Dose Administration (AUC[O-24h]md) | Area under the concentration versus time curve from zero to 24 hours of BAY1143572 in plasma after multiple dose administration was measured. | Pre-dose up to 24 hours post-dose on Cycle 1 Day 15 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Subjects With Leukemia Response | Bone marrow aspirates / biopsies / peripheral whole blood were taken and assessed for leukemia response evaluation. Assessment of response was made based on the revised recommendations of the International Working Group (Cheson 2003 criteria). Criteria proposed by Cheson 2003 for leukemia: complete remission (CR), morphological CR with incomplete blood count recovery (CRi), partial remission (PR), no response / treatment failure, relapse from CR, CRi, or PR. |
Not provided
Inclusion Criteria:
Male or female subjects aged >/=18 years
Subjects with a histologically or cytologically confirmed acute leukemia who are refractory to or have exhausted all available therapies
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Life expectancy of at least 12 weeks
Adequate liver and renal functions as assessed by the following laboratory requirements to be conducted within 14 days before the first dose of study drug:
Negative serum or urine pregnancy test must be obtained within 7 days before the first dose of study drug in women of childbearing potential. Negative results must be available before study drug administration
Women and men of reproductive potential must agree to use highly effective contraception when sexually active. This applies for the period between signing of the informed consent and 30 days after the last administration of study drug. Highly effective contraception includes a hormonal contraception with implants or combined oral contraceptives, certain intrauterine devices, bilateral tubal ligation, hysterectomy, or vasectomy of the partner. In addition, the use of condoms for subjects or their partners is required.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | ||
| Hackensack University Medical Center |
Not provided
| ID | Term |
|---|---|
| D007938 | Leukemia |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000625640 | atuveciclib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Subjects received BAY1143572 200 mg tablet orally once daily from Cycle 1 Day 1 of each cycle. |
|
| 240 mg BAY1143572 | Experimental | Subjects received BAY1143572 240 mg tablet orally once daily from Cycle 1 Day 1 of each cycle. |
|
|
| Area Under the Concentration Versus Time Curve from Zero to Last Data Point Greater than Lower Limit of Quantitation (LLOQ) of BAY1143572 in Plasma (AUC[0-tlast]) after Single Dose Administration |
Area under the concentration versus time curve from zero to last data point greater than lower limit of quantitation of BAY1143572 in plasma after single dose administration was measured. |
| Pre-dose up to 24 hours post-dose on Cycle 1 Day 1 |
| Time to Reach Maximum Drug Concentration (tmax) of BAY1143572 in Plasma after Single Dose Administration | Time to reach maximum drug concentration of BAY1143572 in plasma after single dose administration was measured. | pre-dose up to 24 hours post-dose on Cycle 1 Day 1 |
| Time to Reach Maximum Drug Concentration of BAY1143572 in Plasma after Multiple Dose Administration (tmax,md) | Time to reach maximum drug concentration of BAY1143572 in plasma after multiple dose administration was measured. | Pre-dose up to 24 hours post-dose on Cycle 1 Day 15 |
| From start of treatment of the first subject until 28 days |
| Number of Subjects with Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) | An adverse event (AE) was any untoward medical occurrence in subject who received study drug without regard to possibility of causal relationship. AEs that started or worsened after first administration of study medication up to 30 days after end of treatment with study medication were considered to be treatment emergent (TE). A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly and another medical important serious event as judged by investigator. SAEs that started or worsened after study drug treatment were recorded as TESAEs. | From start of study drug administration up to 30 days after the last dose of study drug administration (approximately 2.5 years) |
| Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC) of BAY1143572 after Single Dose Administration in Plasma | Area under the concentration versus time curve from zero to infinity of BAY1143572 after single dose administration in plasma was measured. | Pre-dose up to 24 hours post-dose on C1D1 |
| Hackensack |
| New Jersey |
| 07601 |
| United States |
| Columbia University Medical Center | New York | New York | 10032 | United States |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | United States |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | United States |
| Universitätsklinikum der Johann Wolfgang Goethe Universität | Frankfurt am Main | Hesse | 60596 | Germany |
| Medizinische Fakultät Carl Gustav Carus | Dresden | Saxony | 01307 | Germany |